Skip to main content
Log in

Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renaland hepatic insufficiency

  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The steady-state intravenous pharmacokinetics of pirenzepine has been investigated in patients with chronic liver disease and others with combined chronic liver disease and renal sufficiency.

The plasma clearance (CL) of Pirenzepine, steady-state plasma concentration Cmin(ss) and dominant half life t1/2γ were not significantly altered in the chronic liver disease group. In patients with renal and hepatic insufficiency, CL was reduced, t1/2γ was prolonged from 11.1 to 19.4 h and Cmin(ss) was elevated from 36 ng/ml to 66 ng/ml compared to healthy controls. Plasma concentrations remained in the therapeutic range and the dosage regimen was well tolerated.

Adjustment of the dose of pirenzepine need be considered only in cases of severe impairment of both renal and hepatic elimination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Carmine AA, Brogden RN (1985) Pirenzepine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. Drugs 30: 85–126

    Google Scholar 

  2. Krakamp B, Tanswell P, Vogel H, Bozler G (1989) Steady-state pharmacokinetics of pirenzepine in patients with differing degrees of renal function impairment. Eur J Clin Pharmacol 36: 75–78

    Google Scholar 

  3. Hammer R, Bozler G, Zimmer A, Koss FW (1977) Pharmakokinetik und Metabolismus von L-S 519 CL2 (Pirenzepin) beim Menschen. Therapiewoche 27: 1575–1593

    Google Scholar 

  4. Kühn HA, Wernze H (1979) Klinische Hepatologie. Thieme, Stuttgart New York

    Google Scholar 

  5. Tanswell P, Kasper W, Zahn G (1986) Automated monoclonal radioimmunoassays for pirenzepine, a selective muscarinic receptor antagonist, in plasma and urine. J Immunol Methods 93: 247–258

    Google Scholar 

  6. Lauterbach F (1987) Intestinal permeation of nonquarternary amines: A study with telenzepine and pirenzepine int he isolated mucosa of guinea pig jejunum and colon. J Pharmacol Exp Ther 243: 1121–1130

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krakamp, B., Tanswell, P., Leidig, P. et al. Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renaland hepatic insufficiency. Eur J Clin Pharmacol 36, 71–73 (1989). https://doi.org/10.1007/BF00561027

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00561027

Key words

Navigation